Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pulmonx (LUNG) Finished Goods (2019 - 2025)

Historic Finished Goods for Pulmonx (LUNG) over the last 7 years, with Q3 2025 value amounting to $13.9 million.

  • Pulmonx's Finished Goods fell 1031.25% to $13.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.9 million, marking a year-over-year decrease of 1031.25%. This contributed to the annual value of $14.7 million for FY2024, which is 775.73% down from last year.
  • Pulmonx's Finished Goods amounted to $13.9 million in Q3 2025, which was down 1031.25% from $13.6 million recorded in Q2 2025.
  • Pulmonx's 5-year Finished Goods high stood at $16.4 million for Q1 2023, and its period low was $8.6 million during Q1 2021.
  • In the last 5 years, Pulmonx's Finished Goods had a median value of $14.7 million in 2024 and averaged $14.2 million.
  • Its Finished Goods has fluctuated over the past 5 years, first soared by 9018.33% in 2021, then crashed by 1448.84% in 2025.
  • Quarter analysis of 5 years shows Pulmonx's Finished Goods stood at $12.0 million in 2021, then soared by 30.03% to $15.6 million in 2022, then grew by 2.12% to $16.0 million in 2023, then decreased by 7.76% to $14.7 million in 2024, then fell by 5.73% to $13.9 million in 2025.
  • Its Finished Goods was $13.9 million in Q3 2025, compared to $13.6 million in Q2 2025 and $14.3 million in Q1 2025.